{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MTD",
  "name": "Mettler-Toledo International",
  "url": "https://frontierpicks.com/dossiers/MTD/",
  "json_url": "https://frontierpicks.com/dossiers/MTD.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Mettler-Toledo's raised 2026 guidance, built on 12% Asia and 7% Europe sales growth, supports further outperformance; the third-quarter report around 29 October 2026 shows whether sales confirm it.",
  "invalidation_trigger": "A daily close below $1,400, well under the 2026-10-09 record close of $1,549.99; or a third-quarter report that cuts full-year guidance of 4% to 5% local currency sales growth.",
  "catalyst_date": "2026-10-29",
  "pick": {
    "id": "P-2026-10-12-MTD",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-12",
    "open_close": 1563.01,
    "kill_level": 1400,
    "kill_basis": "daily",
    "horizon_end": "2027-01-12",
    "last_date": "2026-10-12",
    "last_close": 1563.01,
    "return_pct": 0,
    "spy_return_pct": 0,
    "excess_pp": 0,
    "kill_distance_pct": 11.64357142857142,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Mettler-Toledo pays no regular dividend; it returns capital to shareholders mainly through share repurchases.",
    "Mettler-Toledo's per-share price is high, above $1,500 in October 2026, so small percentage moves are large dollar moves per share."
  ],
  "body_markdown": "## Current Thesis\n\nMettler-Toledo's second-quarter beat and raised full-year guidance support continued outperformance, because demand in Asia and Europe is offsetting a soft Americas business. The third-quarter report, expected around 2026-10-29, decides whether that holds. The shares closed at a record $1,549.99 on 2026-10-09, so the report has to confirm guidance, not just meet it.\n\nThe company makes precision weighing and laboratory instruments sold to drug makers, chemical producers, food companies and industrial plants. Its 2026-07-30 release showed local currency sales up 6% excluding a one-time tariff refund to customers, and adjusted earnings per share (EPS) of $11.46, up 14%. Management raised full-year local currency sales growth guidance to 4% to 5% from about 4%, and set adjusted EPS guidance at $47.15 to $47.50.\n\nThe narrative is maturing: Mettler-Toledo is a long-followed compounder, and company news in the 30 days to 2026-10-11 was limited to Barclays raising its target on 2026-10-07 and a retrospective on 20-year returns on 2026-09-17.\n\n## Bull Case\n\n- **Guidance moved up in July.** On 2026-07-30 the company raised its 2026 local currency sales growth outlook to 4% to 5% from about 4% and guided adjusted EPS to $47.15–$47.50.\n- **Asia and Europe are carrying growth.** Second-quarter sales rose 12% in Asia/Rest of World and 7% in Europe, and Chief Executive Patrick Kaltenbach cited \"very good growth in China and emerging markets\" in the 2026-07-30 release.\n- **Earnings grow faster than sales.** Adjusted EPS rose 14% in the second quarter on sales up 4% in dollars to $1.027 billion, per the company's 2026-07-30 release.\n- **Cash flow funds steady buybacks.** The company reported $247 million of free cash flow and $206.3 million of share repurchases in the second quarter of 2026.\n- **Analyst targets are rising.** Barclays kept an Overweight rating and raised its price target to $1,700 on 2026-10-07.\n\n## Bear Case\n\n- **The Americas are shrinking.** Second-quarter sales in the Americas fell 3%, per the 2026-07-30 release, so US pharma and industrial spending is not yet contributing.\n- **Third-quarter guidance is modest.** The company guided third-quarter local currency sales up about 4% and adjusted EPS of $12.00–$12.15, growth of 8% to 9%, per its 2026-07-30 outlook. That is a slower pace than the second quarter's 14% EPS gain.\n- **Tariff items cloud the comparison.** The second-quarter sales figures include a one-time tariff refund to customers, which makes underlying growth harder to read from the headline numbers.\n- **The shares are stretched into the report.** The 14-day relative strength index (RSI) stood at 70.8 on 2026-10-09, at the 52-week high, with the report about three weeks away.\n\n## Setup & Price Structure\n\nThe shares closed at $1,549.99 on 2026-10-09, a new 52-week high, after rising 17.9% over three months, per adjusted daily closes. An RSI of 70.8 marks the move as overbought on that measure.\n\nCrowding signs are observable but moderate. The stock sits at its high with no gap between price and peak, and the next earnings report falls inside the next 30 days. Retail-oriented news coverage is light: two items in the past month. Barclays' $1,700 target sits above the 2026-10-09 close.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-10-29, est. third-quarter 2026 results.** Market data aggregators expect the release after the close, with the call the next morning, matching the 2026-07-30 release and 2026-07-31 call pattern. The company has not confirmed the date. The report tests the guided adjusted EPS of $12.00–$12.15 and about 4% local currency growth. It also shows whether the Americas returned to growth and whether the 4% to 5% full-year sales outlook holds.\n\n## What Would Change Our Mind\n\nThe case breaks if the third-quarter report shows local currency sales growth below the guided level of about 4%, or if full-year guidance is cut from 4% to 5% sales growth and $47.15–$47.50 adjusted EPS. A second straight quarter of falling Americas sales, alongside slower growth in China, would remove the main support for the growth outlook.\n\nOn price, a daily close below $1,400 would put the shares well under the 2026-10-09 record close of $1,549.99. A drop that deep would mean the market has rejected the July upgrade to guidance.\n\n## Correlation Notes\n\nMettler-Toledo trades with laboratory and life-science tools makers, whose shares move together on drug-maker and biotech spending, China demand and the dollar. The site's medtech and diagnostics group, which includes Illumina, Revvity and Intuitive Surgical, has gained attention in each weekly reading from 2026-09-27 to 2026-10-11. Group strength helps the shares, but it does not replace the company's own quarterly results. A broad sell-off in the tools group after peer reports in late October would weigh on the shares whatever Mettler-Toledo reports. Because about half of revenue comes from outside the Americas, a weaker dollar lifts reported sales: second-quarter dollar sales rose 4% while local currency sales excluding the tariff refund rose 6%.",
  "first_seen": "2026-10-11",
  "last_analyzed": "2026-10-11T11:01:27+00:00",
  "last_synthesized": "2026-10-11",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}